Emtricitabine in Chronic Hepatitis B: A Mini Review

Emilio Palumbo

Emtricitabine in Chronic Hepatitis B: A Mini Review

Emilio Palumbo ^{1
, *}

Author Information

¹ Clinic of Pediatrics, Hospital of Sondrio, emipalu2003@yahoo.it, Italy

Article information

Hepatitis Monthly: , 8 (2); 125-127
Article Type: Review Article
Received: March 1, 2008
Accepted: June 10, 2008

To Cite: Palumbo E. Emtricitabine in Chronic Hepatitis B: A Mini Review, Hepat Mon. Online ahead of Print ;8(2):125-127.

Abstract

Emtricitabine is a cytosine nucleoside analog with antiviral activity against both hepatitis B virus (HBV) and human immunodeficiency virus (HIV). It is structurally similar to lamivudine; it differs only by a fluorine at the 5-position of the nucleic acid. This review focuses on the efficacy and tolerability of FTC in the treatment of chronic hepatitis B, both HBeAg and anti-HBe-positive. Relevant literature was identified through searches of MEDLINE (2001-January 2008). The review of literature suggests that the role of emtricitabine as monotherapy may be limited by its structural similarity to lamivudine and the corresponding risk of development of drug resistance; however, some studies seem to evidence an efficacy for emtricitabine in association with other antiviral drugs, as adefovir dipivoxil and clevudine. Other studies are needed to evaluate the efficacy of this new drug in particular in association with other antiviral drugs.

© 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.